Formulation of a Danazol Cocrystal with Controlled Supersaturation Plays an Essential Role in Improving Bioavailability
article
OA: bronze
CC0
⤵ 3 in-corpus citations
AI-generated summary
A danazol:vanillin cocrystal's bioavailability was improved over 10-fold by a supersaturating formulation containing vitamin E-TPGS and Klucel LF Pharm, compared to a neat suspension.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Cocrystals have become an established and adopted approach for creating crystalline solids with improved physical properties, but incorporating cocrystals into enabling pre-clinical formulations suitable for animal dosing has received limited attention. The dominant approach to in vivo evaluation of cocrystals has focused on deliberately excluding additional formulation in favor of "neat" aqueous suspensions of cocrystals or loading neat cocrystal material into capsules. However, this study demonstrates that, in order to take advantage of the improved solubility of a 1:1 danazol:vanillin cocrystal, a suitable formulation was required. The neat aqueous suspension of the danazol:vanillin cocrystal had a modest in vivo improvement of 1.7 times higher area under the curve compared to the poorly soluble crystal form of danazol dosed under identical conditions, but the formulated aqueous suspension containing 1% vitamin E-TPGS (TPGS) and 2% Klucel LF Pharm hydroxypropylcellulose improved the bioavailability of the cocrystal by over 10 times compared to the poorly soluble danazol polymorph. In vitro powder dissolution data obtained under non-sink biorelevant conditions correlate with in vivo data in rats following 20 mg/kg doses of danazol. In the case of the danazol:vanillin cocrystal, using a combination of cocrystal, solubilizer, and precipitation inhibitor in a designed supersaturating drug delivery system resulted in a dramatic improvement in the bioavailability. When suspensions of neat cocrystal material fail to return the anticipated bioavailability increase, a supersaturating formulation may be able to create the conditions required for the increased cocrystal solubility to be translated into improved in vivo absorption at levels competitive with existing formulation approaches used to overcome solubility limited bioavailability.
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (79)
- Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles via openalex
- A liquid chromatographic method for the determination of danazol in human serum via openalex
- Bioavailability of danazol-hydroxypropyl-β-cylodextrin complex by different routes of administration via openalex
- Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates via openalex
- Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug via openalex
- Incomplete Desorption of Liquid Excipients Reduces the <i>in Vitro</i> and <i>in Vivo</i> Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier via openalex
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers via openalex
- Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
- Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex
- doi:10.1016/j.ejps.2011.11.025 via openalex
- doi:10.1007/s11095-010-0269-5 via openalex
- doi:10.1007/s11095-006-9032-3 via openalex
- doi:10.1002/jps.21650 via openalex
- doi:10.1007/s11095-008-9641-0 via openalex
- doi:10.1002/jps.22760 via openalex
- doi:10.1016/j.ijpharm.2004.01.014 via openalex
- doi:10.1021/cg1002176 via openalex
- doi:10.1007/s11095-011-0623-2 via openalex
- doi:10.1021/cg060742p via openalex
- doi:10.1016/j.ijpharm.2011.07.045 via openalex
- doi:10.1021/cg201590j via openalex
- doi:10.1021/cg200462g via openalex
- doi:10.14227/dt160309p41 via openalex
- doi:10.1016/j.ijpharm.2007.09.042 via openalex
- doi:10.1002/jps.21280 via openalex
- doi:10.1517/17425255.2.4.591 via openalex
- doi:10.1002/jps.22154 via openalex
- doi:10.1021/mp100117k via openalex
- doi:10.1021/mp200460u via openalex
- doi:10.1002/jps.22725 via openalex
- doi:10.1002/jps.23306 via openalex
- doi:10.1016/j.ejpb.2006.12.016 via openalex
- doi:10.1016/j.ejpb.2007.05.009 via openalex
- doi:10.1211/jpp.60.1.0008 via openalex
- doi:10.1021/mp300104s via openalex
- doi:10.1002/jps.22033 via openalex
- doi:10.3109/03639045.2011.602406 via openalex
- doi:10.1021/cg801039j via openalex
- doi:10.1016/j.fct.2010.08.023 via openalex
- doi:10.1016/j.ijpharm.2007.05.006 via openalex
- doi:10.1007/s11095-011-0399-4 via openalex
- doi:10.1016/j.ejps.2011.04.016 via openalex
- doi:10.1002/jps.22579 via openalex
- doi:10.1016/j.ejps.2009.10.005 via openalex
- doi:10.1208/s12249-011-9646-6 via openalex
- doi:10.1016/j.jala.2009.12.001 via openalex
- doi:10.1039/b715396a via openalex
- doi:10.1016/s0378-4274(03)90199-8 via openalex
- doi:10.1021/mp200209j via openalex
- doi:10.1039/b703292g via openalex
- doi:10.1023/b:pham.0000016235.32639.23 via openalex
- doi:10.1021/mp300169c via openalex
- doi:10.1021/mp200181v via openalex
- doi:10.1002/bdd.1792 via openalex
- doi:10.1016/j.cmpb.2010.01.007 via openalex
- doi:10.1081/ddc-120028718 via openalex
- doi:10.1016/j.ijpharm.2012.10.043 via openalex
- doi:10.1007/s11095-008-9637-9 via openalex
- doi:10.1021/cg200492w via openalex
- doi:10.1021/mp200352q via openalex
- doi:10.1021/jm1002638 via openalex
- doi:10.1023/a:1016068705255 via openalex
- doi:10.1021/ar00172a005 via openalex
- doi:10.1016/s1461-5347(98)00097-2 via openalex
- doi:10.1021/cg901010v via openalex
- doi:10.1016/j.ijpharm.2010.03.040 via openalex
- doi:10.1111/j.2042-7158.2010.01189.x via openalex
- doi:10.1039/b815174a via openalex
- doi:10.1039/c1ce05381g via openalex
- doi:10.1021/mp300164u via openalex
- doi:10.1208/s12248-012-9337-6 via openalex
- doi:10.3109/1061186x.2010.525652 via openalex
- doi:10.1023/b:pham.0000016283.87709.a9 via openalex
- doi:10.1002/jps.20553 via openalex
- doi:10.1007/s11095-009-0021-1 via openalex
- doi:10.1007/s11095-008-9676-2 via openalex
- doi:10.1016/j.ijpharm.2012.04.075 via openalex
- doi:10.1002/jps.23025 via openalex
- doi:10.1002/jps.22502 via openalex
Cited by (3)
Source provenance
- openalex
- last seen: 2026-05-10T11:21:38.221344+00:00
License: CC0
· commercial use OK